Emetine Hydrochloride
PreclinicalSmall molecule
Emetine Hydrochloride is one of 4 small molecule programs targeting Dengue. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
7 competitors in Dengue
#DrugCompanyPhaseTrials
1Lagevrio
Merck & Co.Phase 2
Rden2δ30-7169
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 1
Biological
NNational Environment Agency, Singapore
Preclinical
Emetine Hydrochloride
JJohns Hopkins University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Dengue1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Emetine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- JJohns Hopkins University